MIM
HUMA icon

MetLife Investment Management’s Humacyte HUMA Stock Holding History

MetLife Investment Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-70,106
Closed -$42.5K – 2916
2026
Q1 		$42.5K Buy
70,106
+57,244
+445% +$59.5K ﹤0.01% 2695
2025
Q4 		$12.4K Sell
12,862
-44,968
-78% -$63.7K ﹤0.01% 2797
2025
Q3 		$101K Sell
57,830
-21,486
-27% -$42.1K ﹤0.01% 2646
2025
Q2 		$166K Buy
79,316
+27,874
+54% +$53.5K ﹤0.01% 2283
2025
Q1 		$87.7K Buy
51,442
+6,482
+14% +$24.3K ﹤0.01% 2584
2024
Q4 		$227K Sell
44,960
-7,335
-14% -$36.3K ﹤0.01% 2242
2024
Q3 		$284K Hold
52,295
– – ﹤0.01% 2095
2024
Q2 		$251K Buy
52,295
+18,301
+54% +$95.2K ﹤0.01% 2109
2024
Q1 		$106K Sell
33,994
-934
-3% -$3.14K ﹤0.01% 2506
2023
Q4 		$99.2K Hold
34,928
– – ﹤0.01% 2610
2023
Q3 		$102K Hold
34,928
– – ﹤0.01% 2563
2023
Q2 		$99.9K Hold
34,928
– – ﹤0.01% 2683
2023
Q1 		$108K Hold
34,928
– – ﹤0.01% 2514
2022
Q4 		$73.7K Buy
+34,928
New +$106K ﹤0.01% 2691

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MetLife Investment Management's HUMA Position: Q2 2026 in Review

MetLife Investment Management sold out of Humacyte (HUMA) in Q2 2026, closing a stake of 70,106 shares — an estimated $42.5K sold.

MetLife Investment Management first reported a position in HUMA in Q4 2022 and held it in 14 quarters. The position peaked at $284K in Q3 2024. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • MetLife Investment Management reported no remaining Humacyte position as of Q2 2026 after selling out during the quarter.
  • MetLife Investment Management sold 70,106 Humacyte shares in Q2 2026, an estimated $42.5K.
  • MetLife Investment Management first reported a position in Humacyte in Q4 2022 and held it in 14 quarters.
  • MetLife Investment Management's Humacyte position peaked at $284K in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.